Select language:  
1800 620 420
Close menu

News

Browse our latest media releases, real stories, newsletter archive, and media hub.

Subscribe here to receive the latest news and stories to your inbox.

Lifeblood

Get inspired by our supporters and read the latest issue of Lifeblood here >

Media hub

Resources for media personnel, including facts and statistics on blood cancer; media contacts; and guidelines for reporting on blood cancer in Australia.

Media releases can be viewed here >

Access the media hub >
Media - 14 June 2021

More Australians with blood cancer reliant on blood donations than ever before

  • Media releases
  • Research
Read more
Illustration of a mobile phone flashing 'News' on the screen

It took the blood of 100 strangers to save my son

To mark World Blood Donor Day on June 14, Jessica Lake shares how her now six-year-old son, Larry, depended on the kindness of blood donors for over a year after being diagnosed with the rare blood disease, aplastic anaemia. 

  • Blood disorders
Read more
Larry Tan_feature
Media - 9 June 2021

National report confirms incidence of blood cancer continues to rise in Australia

  • Media releases
  • Research
Read more
Illustration of a mobile phone flashing 'News' on the screen

Diagnosed with MDS, AML, then MDS again

Tony Wakely’s diagnosis with MDS quickly transformed to AML, which he beat with a transplant. But a year later, he was shocked to find out his MDS had come back.

  • Acute myeloid leukaemia
  • Myelodysplastic syndromes
Read more
Tony and Karen Wakely

International precision medicine clinical trials recruiting

Two new international clinical trials are expected to improve access to new therapies for Australians with MDS as part of the Leukaemia Foundation’s Trials Enabling Program (TEP).

  • Myelodysplastic syndromes
  • Research
Read more
AMLM23 Principal Investigator, Professor Paula Marlton

PBAC update on new MDS & CMML treatment

The Leukaemia Foundation provided consumer comments to the Pharmaceutical Benefits Advisory Committee (PBAC) in relation to Otsuka Australia Pharmaceutical’s resubmission for decitabine and cedazuridine (Inqovi®) for high-risk MDS and CMML.

  • Myelodysplastic syndromes
  • Treatments and side-effects
Read more
CMML under microscope